PharmaFocus Today – Page 17 – media

GE Healthcare launches its first CT production line in the country

Recently, GE Healthcare launched its first CT production line in France, marking a significant expansion of the company’s business at its Booker factory in the Yvelines department of France. It is reported that the new production line was announced in 2023 with the aim of improving the company’s agility, reducing carbon emissions, and better serving European customers. At present, the first scanner assembled in France, the Revolution Maxima CT, has been installed in the emergency department of Montargis Hospital Center in Loiret. The assembly of Revolution Maxima CT at Buc factory includes all functions and X-ray testing, system configuration, and direct delivery to European customers, which helps simplify the supply chain. It is understood that the new production line is part of GE Healthcare’s “In Europe for Europe” program, which is expected to reduce carbon emissions related to scanner transportation in Europe by 84%. This reduction is mainly due to ...
- Source: drugdu
- 76
- October 24, 2024
Boston Scientific’s’ 2 Medical Devices’ Approved for Market by FDA

On October 21st, according to foreign media Fierce Biotech, the FARAWAVE NAV ablation catheter and Faraview software integrated with Boston Scientific’s navigation function have been approved by the US Food and Drug Administration (FDA). It is reported that the above two products have been officially launched in the United States, forming part of the Boston Scientific Farapulse Pulsed Field Ablation (PFA) system, providing a new visualization solution for cardiac ablation surgery. New features added The FARAWAVE NAV ablation catheter is an upgrade based on the previous generation PFA product FARAPULSE. It looks very similar to the FARAPULSE ablation catheter in appearance, but the new generation product has many new features that were not present in the previous generation product – magnetic navigation function and equipped with a dedicated 3D FARAVIEW module (software). Therefore, this also enables the FARAWAVE NAV ablation catheter to have both ablation and mapping functions:  Ablation ...
- Source: drugdu
- 80
- October 24, 2024
When Hengrui Medicine “gave up” going overseas independently

Going overseas is not only a dream, but also a big adventure that Hengrui Medicine has to take. Even under the new measurement standards, there is such a voice that the success of going overseas will be the key to determining whether Hengrui Medicine can maintain its “number one” status. Indeed, Hengrui Medicine, which has accelerated its innovation transformation, has come to a crossroads. First, relying on the domestic market in the past, Hengrui Medicine may not be in a hurry to layout overseas markets. However, with the involution of domestic innovative drugs and pharmaceutical companies going overseas to find incremental growth, internationalization has also been raised to a more important level. Although Hengrui Medicine proposed the direction of “internationalization” as early as in its 2020 annual report, its internationalization has not been smooth in the past few years. Secondly, carrelizumab has already fallen behind, and the internationalization of PD-1 ...
- Source: drugdu
- 64
- October 24, 2024
Going overseas in the storm of price cuts

This year, “going overseas” is still a hot keyword in the medical device industry. Especially at present, the domestic medical device market has entered a plateau period, and local “roll kings” are increasingly aware of the importance of going overseas. A positive signal is that the recognition of Chinese medical devices in overseas markets is constantly rising. At the just-concluded CMEF Autumn Exhibition, participants could clearly feel that international friends have become more enthusiastic about the Chinese medical device exhibition. According to the organizer, the number of pre-registrations for international visitors at this year’s exhibition exceeded twice that of the same period last year. On the background walls of the booths of some local exhibitors, large-scale introductions to companies and products and services are printed in English, which can be said to have spared no effort in attracting overseas attention. The cost advantages of Chinese medical devices and the product ...
- Source: drugdu
- 61
- October 24, 2024
Jixing Announces that the National Medical Products Administration has accepted the New Drug Marketing Authorization Application for Aficamten Tablets

October 18, 2024, Shanghai, China – Jixing Pharmaceuticals (hereinafter referred to as “Jixing”), a biotechnology company committed to bringing innovative science and drugs to patients suffering from serious life-threatening cardiometabolic diseases, today Announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has officially accepted the new drug marketing application for Aficamten tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a new generation of selective small molecule cardiac myosin inhibitor under development. Its treatment of oHCM has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) and the China National Medical Products Administration. This new drug marketing application is based on the positive results of the pivotal global Phase 3 clinical study SEQUOIA-HCM. A total of 282 patients with obstructive HCM were enrolled in SEQUOIA-HCM. The study results showed that treatment with Aficamten significantly improved patients’ exercise capacity ...
- Source: drugdu
- 74
- October 24, 2024
Sufficient Supply of Influenza Vaccines in Shandong; Elderly Vaccination Rate at 54.57%

On October 22, the Shandong Provincial Government Information Office held a press conference to introduce the province’s efforts in enhancing the integration of healthcare and elderly care, as well as promoting healthy aging. It was reported that Shandong currently has a sufficient supply of influenza vaccines, having completed 2.67 million doses of vaccinations, with elderly individuals accounting for 54.57% of those vaccinated. As the weather turns colder, infectious diseases such as influenza and pneumonia enter their peak season, and the elderly are a major susceptible group. It was noted that over 3,200 medical institutions in Shandong have activated a real-time monitoring and reporting network for infectious diseases, focusing particularly on the incidence of diseases among the elderly and other key populations. Vaccination against influenza and pneumonia not only reduces infection risks but also effectively lowers the incidence of severe cases, making it one of the primary measures for the prevention ...
- Source: drugdu
- 68
- October 24, 2024
75.4 billion! Abbott’s Q3 performance exceeded expectations

Yesterday (October 17th), Abbott announced its third quarter 2024 financial report on its official WeChat account. Abbott’s global sales in the third quarter reached 10.6 billion US dollars (approximately 75.48 billion yuan), with an organic growth of 8.2% and a reported sales growth of 4.9%. Based on the brilliant performance in this quarter, Abbott said that after excluding the impact of COVID-19 testing products, the company expects global sales to achieve an organic growth of 9.5% to 10.0% in 2024, and diluted earnings per share after adjustment for the whole year may be between 4.64 and 4.70 dollars, the median of the range is higher than the previous estimate. Continuous growth achieved through multiple business operations According to the financial report, Abbott’s multiple departments have achieved business growth. Among them, the medical device department achieved double-digit growth, with global sales reaching $4.7 billion in the third quarter, an organic growth ...
- Source: drugdu
- 74
- October 23, 2024
7 Innovative Medical Devices Enter Special Review Process

Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 9 of 2024), intending to approve 7 innovative medical device projects to enter the special review process.1. Liver low-temperature perfusion system: Hangzhou Lepusheng Medical Technology Co., Ltd Hangzhou Lepusheng Medical Technology Co., Ltd. (hereinafter referred to as Lepusheng Medical) was founded in 2016, focusing on the independent research and development of advanced medical devices for the protection, preservation, repair, and transportation of transplanted organs. It is committed to becoming a domestic benchmark and a global leading solution provider in the field of organ perfusion preservation and resuscitation. Since its establishment, Lepusheng Medical has made breakthroughs in core technologies such as organ perfusion protection and transport repair, and is opening up a new model for organ protection in China. The research and development focus of Lepusheng Medical is on ...
- Source: drugdu
- 72
- October 23, 2024
Cell Stem Cell | Drug Sensitivity and Resistance Atlas of Sarcoma

Writing | My Best Friend Old Red Riding Hood Sarcoma is a rare heterogeneous stromal tumor. They mainly occur in bones and soft tissues, and have a particularly severe impact on young patients [1-3]. In the United States, about 13000 cases of soft tissue sarcoma and 4000 cases of osteosarcoma are diagnosed every year. Although the incidence rate is very low, the mortality rate is still high. For example, osteosarcoma is the third leading cause of cancer death in patients under the age of 20. The treatment plan varies depending on the subtype and stage of the disease, including surgical resection, chemotherapy, targeted systemic therapy, and in some cases, radiation therapy [4,5]. Although significant progress has been made in specific subtypes, current treatment methods rarely cure them. The overall 5-year survival rate for soft tissue sarcoma is 65%, and the overall 5-year survival rate for bone cancer is 50% -60% ...
- Source: drugdu
- 65
- October 23, 2024
The mechanism by which G protein mutations lead to excessive activation of T cells through non classical pathways

Writing | Snow Moon G protein coupled receptors (GPCRs) guide cellular responses to environmental signals, including hormones, neurotransmitters, and chemokines. This process is achieved through a complex biochemical cycle mediated by heterotrimeric G protein. After GPCR binds to the ligand, the G α subunit binds to GTP, becomes active, and separates from the G β – γ complex and GPCR. The separated G α – guanosine triphosphate (GTP) and free G β – γ initiate downstream signaling, including the generation of second messengers, biochemical interactions, and ion channel changes. The GTPase activity of G α hydrolyzes GTP to guanosine diphosphate (GDP), thereby terminating signal transduction and allowing Gabg to reassemble with GPCRs, enabling cells to respond to reactivation of GPCRs. In the G α protein family, the Gai/o family includes inhibitory subtypes that regulate biological responses by inhibiting the production of cyclic adenosine monophosphate (cAMP) by adenyl cyclase AC. AC ...
- Source: drugdu
- 74
- October 23, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.